Menu

Pharmaceuticals

 

 

Phase III study showed Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy

, , , ,

TECENTRIQ showed significant improvement in overall survival for people regardless of their PD-L1 status Data will be discussed with global health authorities, including the U.S. Food and Drug Administration (FDA) September 1, 2016 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results for TECENTRIQ® from the Phase III study, OAK. The study met […]

Fighting Prescription Drug Misuse through Community Programs: Cardinal Health Foundation Announces Generation Rx Medication Disposal Grants

, , ,

DUBLIN, Ohio, Aug. 31, 2016 /PRNewswire/ — Non-profit organizations across the country were awarded grants from the Cardinal Health Foundation to help fight prescription drug misuse by improving their communities’ medication disposal programs. According to the 2013 National Survey on Drug Use and Health, nearly 70% of those who misuse prescription drugs get them from […]

XALKORI® (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer

, , , ,

XALKORI is the first and only approved biomarker-driven therapy for ROS1-positive advanced NSCLC in the EU Wednesday, August 31, 2016 – “The European Commission’s decision to approve XALKORI for ROS1-positive advanced NSCLC represents an important milestone for patients who previously had limited treatment options” Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved […]

Sanofi and Regeneron Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016

, , , ,

ODYSSEY ESCAPE data concurrently published in the European Heart Journal Paris, France and Tarrytown, New York – August 29, 2016 – Sanofi and Regeneron Pharmaceuticals, Inc. today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous […]

Mylan to Launch First Generic to EpiPen® Auto-Injector at a List Price of $300 per Two-Pack Carton, a More than 50% Discount to the Brand Product

, , ,

HERTFORDSHIRE, England and PITTSBURGH, Aug. 29, 2016 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced that its U.S. subsidiary will launch the first generic to EpiPen® Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen® two-pack carton, which represents a discount of more than 50% to the Mylan list price, […]

Pfizer To Acquire Small Molecule Anti-Infective Business From AstraZeneca

, , ,

Strong fit with Pfizer’s existing anti-infective portfolio Pfizer’s focus on infectious disease and expertise in this category will help enable broader access to anti-infective portfolio Expected to enhance near-term revenue growth potential for Pfizer’s Essential Health business August 24, 2016 – Pfizer Inc. (NYSE:PFE) today announced that it has entered into an agreement with AstraZeneca […]

Pfizer To Acquire Medivation

, , , ,

Propels Pfizer into a leading position in oncology Medivation agrees to transaction valued at $81.50 per Medivation share in cash, for a total enterprise value of approximately $14 billion Expected to be immediately accretive to Pfizer’s Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with additional accretion and growth […]

Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in Cambridge, MA

, , , ,

Transaction formally closed in the first quarter of 2016 / Laboratory and office space will be near Kendall Square in Cambridge, MA / Hiring is underway and efforts have begun on initial programs in hematology and ophthalmology Leverkusen, Germany and Basel, Switzerland, August 19, 2016 – Casebia Therapeutics, the joint venture founded by Bayer and […]

FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain

, ,

August 19, 2016 – Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral use, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. TROXYCA […]

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

, , , ,

August 8, 2016 KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with recurrent or […]

«‹ 8 9 10 11›»